Ceftobiprole is a fifth-generation cephalosporin antibiotic used to treat serious bacterial infections. It’s particularly notable for its broad-spectrum activity, including effectiveness against:
-
Methicillin-resistant Staphylococcus aureus (MRSA)
-
Streptococcus pneumoniae (including drug-resistant strains)
-
Pseudomonas aeruginosa
-
Enterobacteriaceae
Key Facts:
-
Brand name: Often marketed as Zevtera or Mabelio (depending on the country).
-
Route of administration: Intravenous (IV) only.
-
Indications: Approved in many regions for the treatment of hospital-acquired pneumonia (HAP) (excluding ventilator-associated pneumonia) and community-acquired pneumonia (CAP) in adults.
-
Mechanism of action: Like other β-lactam antibiotics, ceftobiprole works by inhibiting bacterial cell wall synthesis, targeting penicillin-binding proteins (PBPs), including PBP2a, which is responsible for MRSA resistance.
Clinical Relevance:
Ceftobiprole is especially valuable in settings where broad coverage is needed before culture results are available, such as in ICU patients or those with suspected drug-resistant pathogens.
<
p data-start=”1212″ data-end=”1313″ data-is-last-node=”” data-is-only-node=””>Would you like to know more about its side effects, clinical trials, or usage in specific infections?